This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Today is only a half-day with a very early start at ASH 2017 in Atlanta, Georgia, then the long trip home.
The last Tuesday at any ASH (American Society of Hematology) Annual Meeting and Exposition is when the late breaking abstracts get presented.
This is reserved for fresh data that was not available at the deadline for the regular submission. Because there is only one such session, blood diseases from leukemia to sickle cell to hemophilia compete for those few spots in front of thousands of hematologists. This oral abstract session is highly coveted by the researchers and highly anticipated by the attendees.
This year the fourth day saw Dr. John Seymour from Australia presenting the Murano trial data that compared a non-chemo combination of venetoclax and rituximab versus bendamustine and rituximab for relapsed and refractory CLL patients. The specific title is: Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia – Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. You can view the abstract here.
This revolutionary non-chemo approach bested the standard of care in all areas of interest to us patients, including overall survival (OS) in chronic lymphocytic leukemia.
This could be game changing
Details to follow.
Can’t wait to get some sleep in my own bed in Socal where it really never snows.
Brian Koffman, MD 12/15/17